A Trial of RSC-1255 for Treatment of Patients With Advanced Malignancies
Phase 1
Recruiting
- Conditions
- RAS MutationLung CancerGlioblastomaPancreatic CancerAdvanced Malignant Solid NeoplasmColon Cancer
- Interventions
- Drug: RSC-1255 Dose EscalationDrug: RSC-1255 Dose Expansion
- First Posted Date
- 2020-12-22
- Last Posted Date
- 2025-05-08
- Lead Sponsor
- RasCal Therapeutics, Inc.
- Target Recruit Count
- 134
- Registration Number
- NCT04678648
- Locations
- 🇺🇸
University of California, Los Angles (UCLA) Department of Medicine - Hematology/Oncology, Los Angeles, California, United States
🇺🇸Sarah Cannon, SCRI Oncology Partners - Health One, Denver, Colorado, United States
🇺🇸Sarah Cannon, SCRI Oncology Partners, Nashville, Tennessee, United States
© Copyright 2025. All Rights Reserved by MedPath